News18 min read
Chinese Peptides: The Gray Market Biohacking Trend Explained
What are "Chinese peptides"? A science-backed analysis of the gray market biohacking trend, safety risks, contamination data, legal status, and how to protect yourself.
News
Industry updates and market analysis.
News16 min read
Peptide Nanotechnology: Drug Delivery Advances
Getting a drug to the right place in the body is often harder than making the drug itself. Cancer therapies that could destroy tumors also poison healthy tissue. Brain drugs that work in the lab cannot cross the blood-brain barrier.
News11 min read
Global Peptide Research Hubs: US, EU, Asia-Pacific
Peptide science has become a global enterprise. With over 100 FDA-approved peptide drugs on the market and a therapeutics sector projected to exceed $100 billion by 2033, institutions worldwide are racing to discover, synthesize, and deliver the next generation of peptide-based medicines.
News12 min read
Peptide Manufacturing Scale-Up Challenges
Making a peptide in a lab is chemistry. Making a million doses of it is engineering, economics, and logistics — and the peptide industry is struggling with all three.
News13 min read
How COVID-19 Accelerated Peptide Research
The pandemic didn't just disrupt daily life — it reshaped the trajectory of peptide science. Between early 2020 and 2023, COVID-19 drove a wave of research funding, clinical experimentation, and public interest that pushed peptides from niche academic study into mainstream biomedical conversation.
News13 min read
Venture Capital in Peptide Startups: 2026 Funding
- [The Money Is Following the Molecules](#the-money-is-following-the-molecules) - [2025 Funding Highlights: The Deals That Defined the Year](#2025-funding-highlights-the-deals-that-defined-the-year) - [Where Investors Are Placing Their Bets](#where-investors-are-placing-their-bets) - [The Corporate
News14 min read
Peptide Delivery Innovations: Patches, Implants, Orals
Most peptide drugs arrive in the body the same way they did 30 years ago: through a needle. Subcutaneous injections work, but they impose a burden that limits who will use peptide therapies and how consistently they'll take them. Needles hurt. They require cold-chain storage.
News12 min read
The GLP-1 Effect on Bariatric Surgery Rates
In 2022, bariatric surgery programs across the United States hit record volumes — 280,000 procedures, the culmination of a decade of steady growth. Two years later, national data showed a 38% decline. The University of Pennsylvania Health System went from 850 annual surgeries to around 400.
News13 min read
The Role of Peptides in Personalized Medicine
One-size-fits-all medicine is a poor fit for peptide therapeutics. A patient on semaglutide might lose 20% of their body weight while another loses 5% — same drug, same dose, vastly different outcomes.
News14 min read
Generic Peptide Drugs: Biosimilar Pipeline
The most prescribed drugs in the world are peptides — and their patents are starting to expire. [Semaglutide](/peptides/semaglutide-complete-pharmacology-guide/) loses patent protection in several major markets in 2026.
News12 min read
Peptide Cosmetics Market: Growth & Innovation
Peptides are the fastest-growing active ingredient category in skincare. The global peptide cosmetics market hit $2.3 billion in 2024 and is projected to exceed $6.5 billion by 2033 — a 12.3% compound annual growth rate.
News13 min read
Peptide Conferences & Events Calendar 2026
- [Why Peptide Conferences Matter in 2026](#why-peptide-conferences-matter-in-2026) - [Major Industry Conferences](#major-industry-conferences) - [Academic and Scientific Meetings](#academic-and-scientific-meetings) - [Specialized and Niche Events](#specialized-and-niche-events) - [What to Expect at
News12 min read
Peptide Therapy Clinics: Industry Growth Analysis
- [The Clinic Boom: How We Got Here](#the-clinic-boom-how-we-got-here) - [Market Size and Growth Projections](#market-size-and-growth-projections) - [Business Models Driving the Industry](#business-models-driving-the-industry) - [Who Is Walking Through the Door](#who-is-walking-through-the-door) -
News14 min read
The Peptide Biohacking Movement: History & Trends
- [From Bodybuilding Forums to Mainstream Culture](#from-bodybuilding-forums-to-mainstream-culture) - [The Origins: How Biohacking Found Peptides](#the-origins-how-biohacking-found-peptides) - [Key Figures Who Shaped the Movement](#key-figures-who-shaped-the-movement) - [The Most Popular Peptides in
News16 min read
Peptide Synthesis Industry: Market & Technology Trends
- [An Industry Under Pressure to Scale](#an-industry-under-pressure-to-scale) - [Market Size and Growth Projections](#market-size-and-growth-projections) - [SPPS: The Workhorse Gets an Upgrade](#spps-the-workhorse-gets-an-upgrade) - [Continuous Flow Synthesis: From Batch to
News12 min read
AI & Machine Learning in Peptide Discovery
- [From Bench to Algorithm: A New Era in Drug Design](#from-bench-to-algorithm-a-new-era-in-drug-design) - [How AI Reshapes Peptide Discovery](#how-ai-reshapes-peptide-discovery) - [AlphaFold and Its Ripple Effects](#alphafold-and-its-ripple-effects) - [De Novo Peptide Design: Building From
News13 min read
Next-Generation GLP-1 Drugs: What's Coming After
**Table of Contents**
News13 min read
The Economics of GLP-1: Impact on Food & Pharma
GLP-1 drugs are no longer just medicines. They are economic forces. When 12.4% of U.S. adults are taking [semaglutide](/peptides/semaglutide-complete-pharmacology-guide/) or [tirzepatide](/peptides/tirzepatide-dual-gipglp-1-agonist-profile/), the effects ripple far beyond clinic walls — into grocery
News10 min read
Major Peptide Clinical Trial Results Expected 2026
2026 is loaded with high-stakes readouts. Four drugs — [retatrutide](/peptides/retatrutide-triple-agonist-research-profile/), [survodutide](/peptides/survodutide-dual-agonist-research-overview/), [orforglipron](/peptides/orforglipron-oral-glp-1-agonist-profile/), and
News16 min read
The Counterfeit Peptide Problem: Industry Response
- [A $103 Billion Gray Market](#a-103-billion-gray-market) - [Types of Counterfeit and Substandard Peptides](#types-of-counterfeit-and-substandard-peptides) - [What Testing Reveals](#what-testing-reveals) - [Health Risks of Counterfeit Peptides](#health-risks-of-counterfeit-peptides) - [How the
News13 min read
Social Media & Peptides: TikTok, Reddit, Influence
- [How Peptides Went Viral](#how-peptides-went-viral) - [TikTok: Kitchen-Counter Pharmacology](#tiktok-kitchen-counter-pharmacology) - [Reddit: The Self-Experimenter's Forum](#reddit-the-self-experimenters-forum) - [YouTube and Podcasts: The Long-Form
News15 min read
The Compounded Semaglutide Controversy Explained
- [A $36 Billion Drug and the Pharmacies That Copied It](#a-36-billion-drug-and-the-pharmacies-that-copied-it) - [What Compounded Semaglutide Actually Is](#what-compounded-semaglutide-actually-is) - [The Shortage That Started Everything (2022-2025)](#the-shortage-that-started-everything-2022-2025) -
News12 min read
GLP-1 Drug Pricing: Global Comparison & Access
- [The Price Tag That Defines a Drug Class](#the-price-tag-that-defines-a-drug-class) - [United States: The World's Most Expensive Market](#united-states-the-worlds-most-expensive-market) - [How Other Countries Pay Less](#how-other-countries-pay-less) - [Country-by-Country Price
News12 min read
Insurance Coverage for GLP-1 Drugs: 2026 Update
- [The Coverage Problem in Plain Terms](#the-coverage-problem-in-plain-terms) - [Medicare Coverage: What Changed in 2026](#medicare-coverage-what-changed-in-2026) - [The GENEROUS Model Explained](#the-generous-model-explained) - [What Medicare Beneficiaries Actually
News12 min read
Celebrity Endorsements & the GLP-1 Phenomenon
- [How Hollywood Made a Diabetes Drug Famous](#how-hollywood-made-a-diabetes-drug-famous) - [The Celebrity Disclosure Timeline](#the-celebrity-disclosure-timeline) - [Social Media as the Accelerant](#social-media-as-the-accelerant) - [Off-Label Use and the Demand
News18 min read
GLP-1 Drugs & the Obesity Treatment Revolution
- [A Disease Reclassified, A Treatment Transformed](#a-disease-reclassified-a-treatment-transformed) - [The Science: How GLP-1 Drugs Work](#the-science-how-glp-1-drugs-work) - [Clinical Evidence: The Numbers That Changed Everything](#clinical-evidence-the-numbers-that-changed-everything) - [Beyond
News14 min read
Peptide Compounding Industry After FDA Crackdown
- [What Happened: The Regulatory Shift in Plain English](#what-happened-the-regulatory-shift-in-plain-english) - [The GLP-1 Compounding Shutdown](#the-glp-1-compounding-shutdown) - [The Broader Peptide Ban: BPC-157, Ipamorelin, and Beyond](#the-broader-peptide-ban-bpc-157-ipamorelin-and-beyond) -
News13 min read
The Rise of Oral Peptide Drugs: Industry Analysis
- [The Pill Problem: Why Peptides Were Injection-Only for Decades](#the-pill-problem-why-peptides-were-injection-only-for-decades) - [SNAC Technology: The Breakthrough Behind Oral Semaglutide](#snac-technology-the-breakthrough-behind-oral-semaglutide) - [Oral Semaglutide: From Rybelsus to the Wegovy
News12 min read
New Peptide Drugs in FDA Pipeline (2026-2028)
**The FDA approved four peptide and oligonucleotide drugs in 2024 and 46 novel drugs overall in 2025.** The next three years promise a wave of peptide approvals that could reshape obesity treatment, autoimmune disease management, and cancer care.
News11 min read
Top Peptide Companies to Watch in 2026
**The peptide therapeutics market is worth over $50 billion and growing fast.** GLP-1 blockbusters get the headlines, but the companies worth watching in 2026 span big pharma, mid-cap biotech, peptide manufacturing specialists, and early-stage startups with novel platforms.
News11 min read
Peptide Therapeutics Market Size & Growth Forecast
**Peptide drugs are no longer a niche pharmaceutical category.** Semaglutide and tirzepatide turned a class of molecules once associated mainly with insulin into the fastest-growing segment in pharma.
News13 min read
Novo Nordisk vs. Eli Lilly: The GLP-1 Market War
**Two pharmaceutical companies. One drug class. Hundreds of billions of dollars at stake.** Novo Nordisk and Eli Lilly have both built their modern identities around GLP-1 receptor agonists, but after a year of diverging trajectories, the competition between them looks less like a rivalry and more
News11 min read
GLP-1 Market Update: Q1 2026 Revenue & Trends
**The GLP-1 drug market has entered its most volatile chapter yet.** Eli Lilly is surging, Novo Nordisk is stumbling, patent cliffs are approaching, and oral formulations just hit pharmacy shelves. Here is where the numbers stand as of early 2026 — and what they mean for the rest of the year.
News12 min read
Peptide Industry News: Weekly Roundup Template
**The peptide space moves fast. New clinical trial results, regulatory shifts, market developments, and research breakthroughs land every week — and separating signal from noise requires context that most news sources don't provide.